Stage Ii Non-small Cell Lung Cancer: Disease Bioinformatics
Lung cancer begins in the lungs and has become the leading cause of cancer deaths in the United States for both men and women--claiming more lives than colon, ovarian, prostate, and breast cancer combined. There are two types of lung cancer--small and non-small--based on the appearance of the cancer cells on the microscope. Non-small cell lung cancer accounts for approximately 85% of lung cancers and include squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Risk for being diagnosed with lung cancer includes smoking, second hand smoke, exposure to radon gas, asbestos, and other chemicals, excessive alcohol use, and a family history. Treatments depend on the stage as well as type of lung cancer but include: surgery, chemotherapy, radiation, targeted drug therapy, and clinical trials. Stage II cancer can be divided into IIA and IIB for non-small cell lung cancer. Differences between IIA and IIB may change treatment plans.
Stage Ii Non-small Cell Lung Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Stage Ii Non-small Cell Lung Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 948 products for the study of Stage Ii Non-small Cell Lung Cancer that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.